Immunome, Inc. (IMNM)
23.42
-0.53
(-2.21%)
USD |
NASDAQ |
Sep 16, 16:00
23.42
0.00 (0.00%)
After-Hours: 16:57
Immunome Debt to Equity Ratio : 0.009 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.009 |
| March 31, 2026 | 0.0063 |
| December 31, 2025 | 0.0061 |
| September 30, 2025 | 0.0152 |
| June 30, 2025 | 0.0154 |
| March 31, 2025 | 0.0155 |
| December 31, 2024 | 0.0267 |
| September 30, 2024 | 0.0127 |
| June 30, 2024 | 0.0109 |
| March 31, 2024 | 0.0057 |
| December 31, 2023 | 0.0138 |
| September 30, 2023 | 0.0375 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0193 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.0037 |
| September 30, 2022 | 0.0078 |
| June 30, 2022 | 0.0062 |
| March 31, 2022 | 0.0051 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.0003 |
| June 30, 2021 | 0.0007 |
| March 31, 2021 | 0.0153 |
| December 31, 2020 | 0.0148 |
| September 30, 2020 | -0.9989 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 565.38M |
| Total Liabilities (Quarterly) | 40.30M |
| Shareholders Equity (Quarterly) | 525.08M |
| Current Ratio | 15.08 |
| Net Debt Paydown Yield | 0.00% |